appropriation; ibogaine; clinical research study

HB 2871 appropriates $10 million from Arizona’s state general fund for a clinical research study on ibogaine’s potential treatment of neurological conditions, specifically traumatic brain injury and post-traumatic stress disorder. The Arizona Department of Health Services must award this grant to a qualified research entity meeting strict criteria, including proven expertise in neurological treatment, advanced neurosurgery facilities, and capacity for innovative neurological research. The bill exempts this funding from standard appropriation lapse rules under Arizona law. This legislation directly affects Arizona’s health research programs and eligible medical institutions conducting the study, with no direct impact on general public services or regulations.